Read this company snapshot
Daily valuation snapshot
Zentalis Pharmaceuticals, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $2.64
- Market capitalization (USD)
- $189,213,852.96
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.32
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ZNTL in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ZNTL in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing ZNTL with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $2.64 |
| Market capitalization (USD) | $189,213,852.96 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.32 |
No matching rows. Clear the filter to see all records.
Read ZNTL's valuation metrics
Company size
Zentalis Pharmaceuticals, Inc. Common Stock's recorded market capitalization is $189,213,852.96. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
ZNTL's recorded price-to-book ratio is 1.32. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Zentalis Pharmaceuticals, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about ZNTL. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ZNTL's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.